Diallyl disulfide (DADS) has been suggested to possess hepatoprotection against
alcoholic liver disease (ALD) by a couple of pilot studies, while the underlying mechanisms remain largely unknown. This study aimed to investigate the hepatoprotective effects of DADS against
ethanol-induced
liver steatosis and early
inflammation by using the chronic-plus-binge mice model and cultured J774A.1 macrophages and AML12 hepatocytes. We found that DADS significantly attenuated
ethanol-induced elevation of serum
aminotransferase activities, accumulation of liver
triglyceride, hepatocytes apoptosis, oxidative stress, infiltration of macrophages and neutrophils, and proinflammatory polarization of macrophages in mice livers. In addition, chronic-plus-
binge drinking induced apparent intestinal mucosa damage and disturbance of gut microbiota,
endotoxemia, and activation of hepatic NF-κB signaling and NLRP3
inflammasome, which was inhibited by DADS. In vitro studies using cocultured AML12/J774A.1 cells showed that DADS suppressed
ethanol/LPS-induced cell injury and inflammatory activation of macrophages. Furthermore, DADS ameliorated
ethanol-induced decline of
peroxisome proliferator-activated receptor α (PPARα),
carnitine palmitoyltransferase 1 (CPT1), and phosphorylated
AMP-activated protein kinase (AMPK)
protein levels in mice livers and AML12 cells. These results demonstrate that DADS could prevent
ethanol-induced
liver steatosis and early
inflammation by regulating the gut-liver axis and maintaining
fatty acid catabolism.